<p>McAdam LLC 在最近向證券交易委員會提交的文件中表示，在第一季度將其在 Vertex Pharmaceuticals Incorporated（納斯達克：VRTX - 免費報告）的持股減少了 76.5%。該基金在此期間出售了 1,679 股後，持有該製藥公司 516 股股票。McAdam LLC 在 Vertex Pharmaceuticals 的持股在最近一個季度末價值 25 萬美元。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也買賣了該公司的股票。Activest Wealth Management 在第一季度新購入了約 25,000 美元的 Vertex Pharmaceuticals 股份。Clal Insurance Enterprises Holdings Ltd 在第一季度將其在 Vertex Pharmaceuticals 的持股增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 現在擁有 55 股該製藥公司的股票，價值約 27,000 美元，此前在上個季度又購買了 45 股。Mascagni Wealth Management Inc.在第四季度新購入了約 31,000 美元的 Vertex Pharmaceuticals 股份。Flaharty Asset Management LLC 在第一季度新購入了約 32,000 美元的 Vertex Pharmaceuticals 股份。最後，Mpwm Advisory Solutions LLC 在第四季度新購入了約 40,000 美元的 Vertex Pharmaceuticals 股份。目前，90.96% 的股票由機構投資者和對沖基金持有。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<h2>Vertex Pharmaceuticals 的內部活動</h2>
<p>在其他 Vertex Pharmaceuticals 的新聞中，董事 Bruce I. Sachs 於 8 月 6 日星期三購買了 5,000 股 Vertex Pharmaceuticals 的股票。該股票的平均購買成本為每股 389.68 美元，總價值為 1,948,400.00 美元。收購完成後，該董事持有該公司 45,000 股股票，價值約 17,535,600 美元。這代表了他們持股的 12.50% 的增長。此次購買在向證券交易委員會的文件中披露，可以通過此超鏈接訪問。內部人士持有該公司 0.20% 的股票。</p>
<h2>Vertex Pharmaceuticals 的價格表現</h2>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p>VRTX 的股票在週五開盤價為 397.37 美元。Vertex Pharmaceuticals Incorporated 的 1 年最低價為 362.50 美元，1 年最高價為 519.88 美元。該股票的市值為 1,018.8 億美元，市盈率為 28.40，貝塔值為 0.44。該公司 50 日移動平均價格為 423.87 美元，200 日移動平均價格為 454.15 美元。</p>
<p>Vertex Pharmaceuticals（納斯達克：VRTX - 獲取免費報告）最近一次公佈財報是在 8 月 4 日星期一。該製藥公司報告季度每股收益為 4.52 美元，超出分析師一致預期的 4.24 美元，超出幅度為 0.28 美元。Vertex Pharmaceuticals 的淨利潤率為 31.86%，股本回報率為 23.91%。該公司在本季度的收入為 29.4 億美元，而分析師預期為 29 億美元。在去年同期，該公司每股收益為（12.83）美元。與去年同期相比，該公司的收入增長了 11.3%。Vertex Pharmaceuticals 已將其 2025 財年的指導目標設定為每股收益。整體而言，股票分析師預計 Vertex Pharmaceuticals Incorporated 在當前財年將發佈 15.63 美元的每股收益。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>Vertex 的止痛藥：大型製藥公司的下一個重大成功？</li>
</ul>
<p>一些分析師最近對 VRTX 股票發佈了報告。Raymond James Financial 在 9 月 2 日星期二開始對 Vertex Pharmaceuticals 的股票進行覆蓋。他們對該公司的評級為 “市場表現”。Truist Financial 在 8 月 5 日星期二對 Vertex Pharmaceuticals 設定了 490.00 美元的目標價，並給予該股票 “買入” 評級。摩根大通將 Vertex Pharmaceuticals 的目標價從 515.00 美元上調至 517.00 美元，並在 7 月 14 日星期一的報告中給予該公司 “增持” 評級。BMO 資本市場在 8 月 5 日星期二的研究報告中對 Vertex Pharmaceuticals 設定了 530.00 美元的目標價，並給予該股票 “跑贏大盤” 評級。最後，Erste Group Bank 在 5 月 23 日星期五的研究報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “持有”。一位研究分析師對該股票給予了 “強烈買入” 評級，十四位分析師給予 “買入” 評級，十三位分析師對該公司的股票給予 “持有” 評級。根據 MarketBeat 的數據，Vertex Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 496.05 美元。</p>
<p><strong>查看我們關於 Vertex Pharmaceuticals 的最新報告</strong></p>
<h2>Vertex Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變的 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更喜歡的五隻股票勝過 Vertex Pharmaceuticals</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>接近阻力的高飛股票：3 只值得關注的股票</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>希捷科技引領標準普爾 500：其 120% 漲幅背後的原因是什麼？</li>
<li>紐約證券交易所的股票為投資者提供多種優質選擇</li>
<li>先鋒的 VUG ETF：您投資組合的終極增長 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛市場注意到之前立即購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

福泰制藥

<p>McAdam LLC 在第一季度將其在 Vertex Pharmaceuticals (NASDAQ:VRTX) 的持股減少了 76.5%，目前持有 516 股，價值 250,000 美元。其他機構投資者也調整了他們的持倉。董事 Bruce I. Sachs 以每股 389.68 美元購買了 5,000 股，增加了 12.5% 的持股比例。Vertex 的股票開盤價為 397.37 美元，市值為 1,018.8 億美元，市盈率為 28.40。該公司報告了上個季度每股收益為 4.52 美元，超出預期，並已設定 2025 財年的每股收益指引。分析師對該股票的評級不一，普遍目標價為 496.05 美元</p>

<p>McAdam LLC decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 76.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 516 shares of the pharmaceutical company's stock after selling 1,679 shares during the period. McAdam LLC's holdings in Vertex Pharmaceuticals were worth $250,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>McAdam LLC 在最近向證券交易委員會提交的文件中表示，在第一季度將其在 Vertex Pharmaceuticals Incorporated（納斯達克：VRTX - 免費報告）的持股減少了 76.5%。該基金在此期間出售了 1,679 股後，持有該製藥公司 516 股股票。McAdam LLC 在 Vertex Pharmaceuticals 的持股在最近一個季度末價值 25 萬美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently bought and sold shares of the company. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $31,000. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, Mpwm Advisory Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也買賣了該公司的股票。Activest Wealth Management 在第一季度新購入了約 25,000 美元的 Vertex Pharmaceuticals 股份。Clal Insurance Enterprises Holdings Ltd 在第一季度將其在 Vertex Pharmaceuticals 的持股增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 現在擁有 55 股該製藥公司的股票，價值約 27,000 美元，此前在上個季度又購買了 45 股。Mascagni Wealth Management Inc.在第四季度新購入了約 31,000 美元的 Vertex Pharmaceuticals 股份。Flaharty Asset Management LLC 在第一季度新購入了約 32,000 美元的 Vertex Pharmaceuticals 股份。最後，Mpwm Advisory Solutions LLC 在第四季度新購入了約 40,000 美元的 Vertex Pharmaceuticals 股份。目前，90.96% 的股票由機構投資者和對沖基金持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Insider Activity at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的內部活動</h2>
</div><p>In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company's stock, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Vertex Pharmaceuticals 的新聞中，董事 Bruce I. Sachs 於 8 月 6 日星期三購買了 5,000 股 Vertex Pharmaceuticals 的股票。該股票的平均購買成本為每股 389.68 美元，總價值為 1,948,400.00 美元。收購完成後，該董事持有該公司 45,000 股股票，價值約 17,535,600 美元。這代表了他們持股的 12.50% 的增長。此次購買在向證券交易委員會的文件中披露，可以通過此超鏈接訪問。內部人士持有該公司 0.20% 的股票。</p>
</div><h2>Vertex Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的價格表現</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p>Shares of VRTX opened at $397.37 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The stock has a market cap of $101.88 billion, a PE ratio of 28.40 and a beta of 0.44. The firm has a fifty day moving average price of $423.87 and a 200 day moving average price of $454.15.</p>
<div class="lb-trans"><p>VRTX 的股票在週五開盤價為 397.37 美元。Vertex Pharmaceuticals Incorporated 的 1 年最低價為 362.50 美元，1 年最高價為 519.88 美元。該股票的市值為 1,018.8 億美元，市盈率為 28.40，貝塔值為 0.44。該公司 50 日移動平均價格為 423.87 美元，200 日移動平均價格為 454.15 美元。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same period in the prior year, the company earned ($12.83) earnings per share. The business's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（納斯達克：VRTX - 獲取免費報告）最近一次公佈財報是在 8 月 4 日星期一。該製藥公司報告季度每股收益為 4.52 美元，超出分析師一致預期的 4.24 美元，超出幅度為 0.28 美元。Vertex Pharmaceuticals 的淨利潤率為 31.86%，股本回報率為 23.91%。該公司在本季度的收入為 29.4 億美元，而分析師預期為 29 億美元。在去年同期，該公司每股收益為（12.83）美元。與去年同期相比，該公司的收入增長了 11.3%。Vertex Pharmaceuticals 已將其 2025 財年的指導目標設定為每股收益。整體而言，股票分析師預計 Vertex Pharmaceuticals Incorporated 在當前財年將發佈 15.63 美元的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Vertex's Pain Drug: Big Pharma's Next Major Success?</li>
</ul>
<div class="lb-trans"><ul>
<li>Vertex 的止痛藥：大型製藥公司的下一個重大成功？</li>
</ul>
</div><p>A number of analysts have recently issued reports on VRTX shares. Raymond James Financial started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a &#34;market perform&#34; rating for the company. Truist Financial set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the stock a &#34;buy&#34; rating in a report on Tuesday, August 5th. JPMorgan Chase &amp; Co. lifted their target price on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, July 14th. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, August 5th. Finally, Erste Group Bank downgraded shares of Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have issued a Hold rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $496.05.</p>
<div class="lb-trans"><p>一些分析師最近對 VRTX 股票發佈了報告。Raymond James Financial 在 9 月 2 日星期二開始對 Vertex Pharmaceuticals 的股票進行覆蓋。他們對該公司的評級為 “市場表現”。Truist Financial 在 8 月 5 日星期二對 Vertex Pharmaceuticals 設定了 490.00 美元的目標價，並給予該股票 “買入” 評級。摩根大通將 Vertex Pharmaceuticals 的目標價從 515.00 美元上調至 517.00 美元，並在 7 月 14 日星期一的報告中給予該公司 “增持” 評級。BMO 資本市場在 8 月 5 日星期二的研究報告中對 Vertex Pharmaceuticals 設定了 530.00 美元的目標價，並給予該股票 “跑贏大盤” 評級。最後，Erste Group Bank 在 5 月 23 日星期五的研究報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “持有”。一位研究分析師對該股票給予了 “強烈買入” 評級，十四位分析師給予 “買入” 評級，十三位分析師對該公司的股票給予 “持有” 評級。根據 MarketBeat 的數據，Vertex Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 496.05 美元。</p>
</div><p><strong>View Our Latest Report on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Vertex Pharmaceuticals 的最新報告</strong></p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變的 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票勝過 Vertex Pharmaceuticals</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>接近阻力的高飛股票：3 只值得關注的股票</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>希捷科技引領標準普爾 500：其 120% 漲幅背後的原因是什麼？</li>
<li>紐約證券交易所的股票為投資者提供多種優質選擇</li>
<li>先鋒的 VUG ETF：您投資組合的終極增長 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛市場注意到之前立即購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

McAdam LLC 出售了福泰製藥公司 $VRTX 的股票